Publication:
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as fi rst-line therapy

Simple item page
dc.contributor.authorManso, L
dc.contributor.authorCiruelos, E
dc.contributor.authorCodes, M
dc.contributor.authorDe la Haba, J
dc.contributor.authorGalan, A
dc.contributor.authorBaena, J
dc.contributor.authorJaen, A
dc.contributor.authorGil, M
dc.contributor.authorMurias, A
dc.contributor.authorBlancas, I
dc.contributor.authorGonzalez, E
dc.contributor.authorPerez, D
dc.contributor.authorBayo, JL
dc.contributor.authorMel, J
dc.contributor.authorGarcia-Martinez, E
dc.contributor.authorCubedo, R
dc.contributor.authorSalvador, J
dc.contributor.authoraffiliation[Manso,L; Ciruelos,E] Hospital 12 de Octubre, Madrid, Spain. [Codes,M] Hospital Virgen Macarena, Sevilla, Spain. [De la Haba,J] Hospital Reina Sofía, Córdoba, Spain. [Galan,A] Hospital de Sagunto, Spain. [Baena,J] Hospital Puerta del Mar, Cádiz, Spain. [Jaen,A] Hospital de Jaen, Spain. [Gil,M] ICO, Bellvitge, Spain. [Murias,A] Hospital Insular, Las Palmas de Gran Canaria, Spain. [Blanca,I] Hospital San Cecilio, Granada, Spain. [Gonzalez,E] Hospital Virgen de las Nieves, Granada, Spain. [Perez,D] Hospital Costa del Sol, Marbella, Spain; [Bayo,JL] Hospital Juan Ramón Jimenez, Huelva, Spain. [Mel,J] Hospital Xeral-Calde, Lugo, Spain. [Garcia-Martinez,E] Hospital Morales Messeguer, Murcia, Spain. [Cubedo,R] Hospital Puerta de Hierro, Madrid, Spain. [Salvador,J] Hospital Universitario de Valme, Sevilla, Spain.es
dc.date.accessioned2016-06-28T09:22:00Z
dc.date.available2016-06-28T09:22:00Z
dc.date.issued2011-11-16
dc.description.abstractCirculating endothelial cells (CECs) are shed from vessels and enter the circulation reflecting endothelial damage. Increased numbers of CECs have been documented in cancer, and appear to correlate with progression of the tumor. Bevacizumab (B) in combination with CT improves progression-free survival (PFS) of first-line treatments and may modify tumor cell intravasation and CEC/CTC levels.es
dc.description.versionYeses
dc.identifier.citationManso L, Ciruelos E, Codes M, De la Haba J, Galan A, Baena J, et al. Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as fi rst-line therapy. Breast Cancer Res. 2011; 13(Suppl 2): P4.es
dc.identifier.doi10.1186/bcr3025
dc.identifier.essn1465-542X
dc.identifier.issn1465-5411
dc.identifier.pmid22165840
dc.identifier.urihttp://hdl.handle.net/10668/2231
dc.journal.titleBreast Cancer Research
dc.language.isoen
dc.organizationAGS Sur de Sevilla
dc.publisherBioMed Centrales
dc.relation.publisherversionhttp://breast-cancer-research.biomedcentral.com/articles/supplements/volume-13-supplement-2es
dc.rights.accessRightsopen access
dc.subjectNeoplasiases
dc.subjectBevacizumabes
dc.subjectAnticuerpos monoclonales humanizadoses
dc.subjectDesoxicitidinaes
dc.subjectProgresión de la enfermedades
dc.subjectCélulas endotelialeses
dc.subjectPaclitaxeles
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanizedes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidinees
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progressiones
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survivales
dc.subject.meshMedical Subject Headings::Anatomy::Cells::Epithelial Cells::Endothelial Cellses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studieses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Diseases::Neoplasmses
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids::Paclitaxeles
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, X-Ray Computedes
dc.titlePrognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as fi rst-line therapyes
dc.typeconference presentation
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Manso_PrognosticValueHighLevel.pdf
Size:
204.75 KB
Format:
Adobe Portable Document Format
Description:
Meeting abstrat
Download

Collections

SAS - Hospital Universitario Virgen Macarena
SAS - Hospital Costa del Sol
SAS - Hospital Universitario de Jaén
SAS - Hospital Universitario Juan Ramón Jiménez
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Reina Sofía
Load more

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía